BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/24/2022 12:41:49 PM | Browse: 255 | Download: 335
 |
Received |
|
2021-08-26 06:33 |
|
Peer-Review Started |
|
2021-08-26 06:36 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-10-22 09:27 |
|
Revised |
|
2021-11-03 01:29 |
|
Second Decision |
|
2022-05-05 03:14 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-05-07 00:45 |
|
Articles in Press |
|
2022-05-07 00:45 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-05-01 19:05 |
|
Typeset the Manuscript |
|
2022-05-13 08:25 |
|
Publish the Manuscript Online |
|
2022-05-24 12:41 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jissy Vijo Poulose and Cessal Thommachan Kainickal |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Cessal Thommachan Kainickal, MBBS, MD, Additional Professor, Department of Radiation Oncology, Regional Cancer Centre, Medical College Campus, Thiruvananthapuram 695011, Kerala, India. drcessalthomas@gmail.com |
| Key Words |
Head and neck squamous cell carcinoma; Recurrent/metastatic head and neck squamous cell carcinoma; Locally advanced head and neck squamous cell carcinoma; Immune checkpoint inhibitors; Immunotherapy; Monoclonal antibody |
| Core Tip |
Immune checkpoint inhibitors have demonstrated better survival outcomes and acceptable toxicity profiles in recurrent/metastatic head and neck squamous cell carcinoma in the first and second-line treatment settings. While anti- programmed cell death protein-1 agents demonstrated efficacy, evidence on the effectiveness of anti-programmed death ligand-1 and anti-cytotoxic T lymphocyte-associated antigen-4 agents is lacking. There is no proven efficacy in the curative setting to date. Gaps in knowledge were found in terms of predictive biomarkers and identification of patients who would benefit from immunotherapy based on biomarker assessment. Several promising trials are currently ongoing to fill this knowledge gap. Novel combination strategies to potentiate and prolong the anti-tumor activity of immune checkpoint inhibitors are also being evaluated currently. |
| Publish Date |
2022-05-24 12:41 |
| Citation |
Poulose JV, Kainickal CT. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials. World J Clin Oncol 2022; 13(5): 388-411 |
| URL |
https://www.wjgnet.com/2218-4333/full/v13/i5/388.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v13.i5.388 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
